Research programme: polycyclic oxazolidinones - Abbott LaboratoriesAlternative Names: A 382535
Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Oxazolidinones; Polycyclic compounds
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer